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 Research highlights:  
- First repetitive data illustrated the combining conventional FISH with flow 
cytometry (FISH-IS) to aneuploidy detection in chronic lymphocytic leukemia 
patients’ samples for a range of chromosome centromere probes (Y, X,9,12).  
 
- This study proved that FISH-IS method is able to accurately differentiate 
between monosomy, disomy and trisomy at the sensitivity threshold of 1% in 
CLL.  
 
- A comparison of three current cytogenetic methods (FISH, laser scanning 
cytometry, FISH-IS) with different abilities in detecting low frequency trisomy 12 




Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous clinical 
course, and prognostication is based on common genetic abnormalities which 
are detected by standard cytogenetic methods. However, current methods are 
restricted by the low number of cells able to be analyzed, resulting in the 
potential to miss clinically relevant sub-clonal populations of cells. A novel 
high throughput methodology called fluorescence in situ hybridization in 
suspension (FISH-IS) incorporates a flow cytometry-based imaging approach 
with automated analysis of thousands of cells. Here we have demonstrated 
that the FISH-IS technique is applicable to aneuploidy detection in CLL 
samples for a range of chromosomes using appropriate centromere probes.  
This method is able to accurately differentiate between monosomy, disomy 
and trisomy with a sensitivity of 1% in CLL. An analysis comparing 
conventional FISH, FISH-IS and laser scanning cytometry (LSC) is presented.    
Key terms:  
FISH in suspension, laser scanning cytometry, centromere, chronic 
lymphocytic leukemia. 





Chronic lymphocytic leukemia (CLL) results from a clonal overgrowth of 
B lymphocytes in the blood and bone marrow, but also involves other 
compartments such as lymph nodes and spleen. It is the most common adult 
leukemia in western countries, usually affecting individuals in their 7th decade 
of life and beyond (1) .  CLL is an extremely heterogeneous disease, and is 
characterized by a highly variable disease course where survival can range 
from months to decades. The current clinical challenge in CLL is 
differentiating between these different clinical courses at diagnosis and also at 
time of first therapy.  To date, the best prognostic and predictive indicators in 
CLL are the presence or absence of chromosomal abnormalities. Patients are 
likely to have a favorable disease course with monosomy del(13q), whereas 
patients with a normal karyotype or trisomy 12 have intermediate outcomes 
and patients with chromosomal deletions of (11q) or (17p) are likely to suffer 
the most aggressive disease course (2, 3). The current treatment for fit CLL 
patients is a combined chemotherapy (Fludarabine and cyclophosphamide) 
and monoclonal antibody (Rituximab, an anti-CD20 monoclonal antibody) 
approach: FCR (4).  The majority of individuals initially respond well to this 
treatment.  However, a proportion of patients will eventually relapse, some 
relatively quickly following treatment.  Early relapses are considered refractory 
to treatment, are associated with clonal evolution and a form of aggressive 
CLL that most often results in the death of the patient.   
Clearly, the use of chemotherapy in these patients as first line therapy 
may not be in the best interest of the patients, particularly in the era of 
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targeted therapies. Being able to identify these patients prior to using DNA 
damaging agents would be preferable. One area of interest in CLL research is 
the role of sub-clonal evolution in the course of this disease.  Due largely to 
the recent advances in sequencing technologies, it is now appreciated that an 
individual cancer, such as CLL, consists of populations of genetically 
heterogeneous cells (5-8). The cancer itself evolves and develops as a result 
of not only the interactions between these genetically different sub-clones, but 
also on the response of each sub-clone to any given treatment.  
Chemotherapy intervention may eradicate treatment-sensitive sub-clones, 
whilst enabling an expansion of the treatment-resistant cell populations (9-11), 
leading to disease relapse and/or chemo-refractoriness in some patients.  
Therefore, there is a pressing clinical need to identify and to better understand 
the biology of small sub-clonal populations which may contain common 
chromosomal alterations at diagnosis, as well as monitoring the dynamic 
changes in these populations during the disease course.  This would inform 
us about the clonal evolution of the disease, and may also guide 
prognostication.  
Currently, cytogenetic tests including both conventional FISH and 
karyotype analysis play a vital role in identifying these chromosomal 
abnormalities. However, they are not suited to detecting small sub-clones or 
repeated monitoring of the disease course. Conventional FISH is analyzed by 
two independent scorers via microscope visualization, and is the current gold 
standard technique for determining cytogenetic abnormalities in CLL.  This 
method assays approximately 200 cells per patient sample, meaning that sub-
clones of cells with a potentially clinically relevant chromosomal abnormality 
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may be missed. This is also operator dependent.  Therefore, although 
conventional FISH is able to identify high-frequency chromosomal 
abnormalities, its sensitivity precludes analysis of sub-clonal populations of 
cells, which may evolve to eventually represent the bulk of the patient’s 
disease at relapse (12, 13).  
An alternative technique to conventional FISH is FISH in suspension 
(FISH-IS), which uses flow cytometry combined with imaging to generate 
high-resolution digital images of individual cells.  FISH-IS is able to analyze 
thousands of cells per second, enabling it to generate information on 100-fold 
more cells from an individual patient sample than conventional FISH.  The 
images which are generated are computer captured, and the associated 
IDEAS software enables automated analysis of this data, quantifying 
characteristics such as cell shape, cell size, fluorescence intensity of the 
hybridized signal, and co-localization of signals (14).  
Another high-throughput FISH method is laser-scanning cytometry 
(LSC), a slide FISH-based technique, which allows high-throughput 
automated quantitative measurements of fluorescence signals captured from 
single cells at a high resolution. The computer-controlled analysis also 
enables investigation of thousands of cells per sample.  
This study is the first to report the FISH-IS methodology for CLL 
samples and to provide a working comparison of the three methodologies 
outlined above. The relatively common CLL chromosomal aneuploidy, trisomy 
12, has been used to compare the three current FISH technologies for relative 
sensitivity, accuracy, time, cost, and clinical applicability.  
Materials and Methods 




Blood was taken from CLL patients with the written consent forms 
(FCREC 216.56). Peripheral blood mononuclear cells (PBMC) were isolated 
by density gradient with Ficoll (Lymph prep), centrifuged at 500 x g for 20 
minutes. The buffy coat cells were collected and centrifuged at 1000 x g for 5 
minutes. Pellets were resuspended in 500 µL RPMI 1640 media 
supplemented with 5% fetal calf serum (FCS) prior to Carnoy‘s fixation. 
Conventional FISH 
Conventional FISH was carried out on PBMCs extracted from CLL patients as 
described previously.  Samples were hybridised with the following Chromosome 
Enumerate Probes (CEP): CEP Y (DYZ1) Spectrum Orange probe, CEP 9 Spectrum 
Orange probe, CEP X (DXZ1) Spectrum Green probe, and CEP 12 (D12Z3) 
Spectrum Green probe. All probes and CEP hybridization buffer were obtained from 
Abbott Molecular (USA).  Samples were processed according to manufacturer’s 
instructions.  Hybridized slides were manually scored by two independent scorers 
through visualization with the appropriate fluorescence channel on an Olympus BX50 
fluorescence microscope. Conventional FISH analysis of 200 nuclei was conducted 
by two independent scorers. The average of the two scores was taken as the final 
result. 
Laser scanning cytometry (LSC)  
The slides were prepared for conventional FISH were analyzed on a 
CompuCyte iCys™ laser scanning cytometer as follows.  Initial low-resolution 
scan with 405 nm wavelength was performed to determine a suitable region.  
Within this region, an area was selected at random for high-resolution 
scanning with the appropriate wavelength for the hybridized probe e.g. 488 
nm for Spectrum Green. The threshold, laser voltage, offset, and any required 
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additional filtering was adjusted on a slide-by-slide basis. The selected area of 
the slide was automatically scanned in 0.2 µm sections overnight. The data 
was analyzed by the iCys software providing a detailed statistical analysis of 
the data collected from the scans, and displaying these data using 
scatterplots and histograms (similar to flow cytometry analysis). Single cells 
were first gated on the nuclear marker (DAPI) based on their size and 
perimeter. In the single cells gate, using statistical analysis software, each 
DAPI stained cell and the number of “green” spots were contoured and 
enumerated. This software provides in-slide position of each cell, therefore, 
allowing the user to cross check the morphology of individual nuclei and 
spots. This permitted the exclusion of those cells in which spots were outside 
the contour of DAPI. Based on the data of more than 2000 nuclei, the 
percentage of two spots and three spots were calculated, therefore identifying 
the trisomy 12 proportion. 
FISH-IS  
The published FISH-IS methods (14, 15) were applied with several 
modifications (Supplementary Table 1). To collect data, the settings were 
applied on the Image StreamX MkII (Amnis, Seattle, USA): channel 1 and 9, 
bright-field was applied to visualize morphology of cells. Channel 2 (480-560 
nm) with laser 488 nm (50 mW) detected Spectrum Green probes 
(Excitation/Emission 496/520 nm). Channel 3 (560-595 nm) with laser 561 nm 
(200 mW) detected Spectrum Orange probes (Excitation/Emission 552/576 
nm). Channel 7 (420-505 nm) with laser 405 nm detected DAPI 
(Excitation/Emission 358/460 nm). Twenty thousand cell events were 
detected at 60x magnification using the lowest flow speed of events. All 
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imaging data was collected with extended depth of field, which enables 
analysis of in-focus spots. To analyse data, the hierarchical gating strategies 
were established using spot wizard in IDEAS Software version 6.1 by: cells 
were gated for the best focus, followed by single cells, and then fluorescence 
spots were assigned with both low and high range intensity. Software 
automatically calculated the number of spot counts by scoring the 
fluorescence FISH signals inside the intact cells. 
Results  
FISH-IS is applicable to CLL patient samples  
To apply this technique to CLL cells, a model of monosomy was used. 
FISH-IS was carried out using the centromere Y probe on male CLL samples 
(n=6). Modified steps to those already published were required to prevent cell 
damage and reduce background and false hybridization (Supplementary 
Figure 1). Following this protocol, cells discriminated into one population 
based on fluorescence, representing 100% of cells with a single spot when 
analyzed with Spot Wizard, confirming that CLL cells are able to be analyzed 
using this technique to accurately detect monosomy in CLL samples 
(Supplementary Figure 2). 
FISH-IS is able to accurately determine ploidy by fluorescence 
intensity on autosomes and sex chromosomes 
Centromeric probe for chromosome 9 (unaffected by the common 
genetic aberrations in CLL), chromosome 12 (common trisomy in CLL) and 
the X chromosome were evaluated using the FISH-IS protocol established 
above.  FISH-IS was able to accurately detect disomy and trisomy in CLL 
samples using these centromere probes (Supplementary Figure 3 and 4).  
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The sensitivity of this detection method was then determined using a 
known ratio mixture of male and female CLL cells hybridized with an X 
chromosome probe, allowing discrimination between monosomy (male CLL 
cells) and disomy (female CLL cells) within the same sample. To ensure the 
observed difference in fluorescence intensity was specifically due to 
hybridization signal and not intrinsic differences affecting hybridization within 
different samples, 50:50 and 80:20 mixtures of two male CLL samples were 
analyzed with the X chromosome probe. This demonstrated 100% 
monosomic cells as expected (Supplementary Figure 5).  
Analysis of these mixed samples with FISH-IS following hybridization 
with the X chromosome centromere probe was performed.  An example of 
FISH-IS carried out on a 10% male: 90% female mixed CLL sample is shown 
in Figure 1.  It is clear that cells discriminate into two populations based on 
their chromosomal content when analyzed by fluorescence intensity (Figure 
1A-C). This analysis demonstrated that FISH-IS is indeed able to discriminate 
between monosomy and disomy by fluorescence intensity.  Furthermore, 
FISH-IS was able to accurately differentiate between monosomic and disomic 
cells down to 1 in 100 cells (1%) (Figure 2 and Supplementary Table 2).  
The ability to detect trisomy 12 in CLL was also confirmed using a CLL 
patient sample previously diagnosed with 95% trisomy 12 by conventional 
FISH (n=200) was analyzed by FISH-IS. The results for this patient sample 
were comparable to standard FISH results, identifying 95.1% trisomy 12 and 
4.9% disomy 12 (n=20,000) (Supplementary Figure 4). 
Spot count needs manual correction to detect ploidy 
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The spot count (Spot Wizard or algorithm spot count) was compared 
with fluorescence intensity as a means of discriminating between monosomic, 
disomic and trisomic CLL sub-clones. However, in all cases, except for the 
detection of 100% monosomy with the Y chromosome centromere probe on 
male samples, the calculated spot count did not accurately estimate the 
expected signal (Figure 3).  
Cell-by-cell images visually inspected revealed two limitations in 
enumerating spots by the spot count software. Firstly, the software was 
unable to discriminate two juxtaposed spots or partially or completely 
superimposed spots (Figure 4D). This issue can be resolved by observing the 
overall fluorescence intensity being greater than for a true single spot. The 
second issue was that spots located outside of the cell were occasionally 
incorrectly counted by spot count. This can be improved by manually 
inspecting the “3-spots” gate (Figure 4E).  
In the example of 10% : 90% male/female mixing experiments, spot count 
demonstrated that 21.8% of cells were classified as having 1-spot (Figure 1D 
and 4F).  Analysis of the overall fluorescence intensity of cells within the 1-
spot gate revealed that there were in fact two populations of cells contained 
within this group: (Figure 4A) those with a fluorescence intensity consistent 
with 2 spots and those consistent with 1 spot. (Figure 4A-C). Therefore, it was 
found that 54.2% of these cells had either partially or entirely overlapping 
signals (R1 accounting for 54.2%), resulting from mistaken identification as a 
single spot by the Spot Wizard software. Additionally, the fluorescence 
intensity was discernible for both of these populations of cells when analyzed 
by a flow cytometry analysis software (FlowJo_V10) (Figure 4C). In addition, 
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manual curation of the 7.3% of cells classified as having 3-spots found that 
93% of these cells actually had 2 spots within the nucleus (marked by DAPI 
staining) in addition to one or more spots outside of this nuclear region (Figure 
4E). After carrying out the manual corrections as described above, the 
percentage of cells contained within the 1-spot population based on 
fluorescence intensity was 10.0%, as expected (Figure 4F). However, it is 
clear that there were a remarkable difference between Wizard analysis and 
manual correction, therefore, our separations of monosomic, disomic and 
trisomic CLL sub-clones identified based on fluorescence intensity of probes.  
This manual re-analysis was applied to the centromere 9 probe and 
demonstrated that 96.4% of cells analyzed using the centromere 9 probe 
showed the expected diploid signal in 100% diploid CLL samples. Similarly, 
the manual correction of centromere 12 recalled 4.89% of the 2-spots and 
94.91 % of 3-spots populations, becoming comparable to the fluorescence 
intensity based analysis (Supplementary Figure 6).  
Comparison of detection of trisomy 12 in CLL samples using three 
different methods 
Trisomy 12 is well established as a common aneuploidy occurring in 
CLL patients and has prognostic relevance. Six Trisomy 12 patient samples 
were analyzed by conventional FISH, LSC and FISH-IS. The CLL samples 
had varying frequencies of trisomy 12 by conventional FISH as the current 
laboratory standard: sample 1 (95% trisomy 12), sample 2 (80% trisomy 12), 
sample 3 (75% trisomy 12), sample 4 (50% trisomy 12), sample 5 (5% trisomy 
12) and control sample 6 (100% diploidy 12). Although LSC and FISH-IS 
analyzed 10-times to 68-times more cells per sample, all methods were found 
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to be comparable in the percentage of trisomy cells. (Supplementary Table 3). 
With high frequency sub-clones, the percentages of trisomy 12 were 
comparable using the three methods, while greater disparity in the estimated 
frequency of small sub-clones was evident. FISH-IS showed lower estimates 
while LSC showed higher estimates compared with conventional FISH (Figure 
5A, B).  
Discussion 
This study has analyzed the applicability of the high throughput method FISH-
IS in accurately identifying monosomy (chromosome Y centromere) and 
disomy (chromosome 9 centromere) and trisomy (chromosome 12 
centromere) in CLL patient samples.   
In analyzing the FISH-IS data, it was clear that the overall fluorescence 
of the cell gave an accurate representation of the hybridization signal, and 
therefore this method could accurately discriminate between 
monosomy/disomy and disomy/trisomy. Unfortunately, whilst the current 
software is able to discriminate between cells with a different number of 
signals by fluorescence intensity, it is less able to correctly determine the 
exact number of signals within these cells, using the ‘spot count’ feature.  
There are several aspects of this system which may be causing this.  The 
software records a 2-dimensional image representation of a 3-dimensional 
object (the cell). Therefore, if spots are at different depths along the same axis 
as the camera, the conversion to a 2-dimensional image may cause the two 
spots to be partially or entirely merged. When manually curating the “1-spot” 
cells, some were easily discernible by eye as being two spots (Figure 4D). 
However, the software was unable to discriminate them as two distinct spots. 
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These issues no doubt contribute to the inaccuracy of the current spot count 
wizard. Previous studies have found a similar level of miscounting spots with 
the current software (14, 16, 17). There is a pressing need for further 
development of this software so that spot counting is an accurate and 
reproducible analysis step, without requiring manual curation and confirmation 
which is a significant limitation of this methodology. 
Conventional FISH is the current standard method for determining 
clinically relevant chromosomal abnormalities in CLL, including trisomy 12.  
Here we have undertaken a limited comparison between conventional FISH 
and two high throughput methods, FISH-IS and LSC, using trisomy 12 as our 
model. Firstly, it is important to recognize that all of these methods rely on the 
successful and accurate hybridization of a labelled probe to the genetic 
material within a cell. Therefore, it follows that these methods, whether high-
throughput or not, are all affected by factors such as probe size, success of 
probe labelling, hybridization technique, and the quality of the cells being 
analyzed. 
The main advantage of conventional FISH is that it is technically simple, only 
requiring access to basic tissue culture facilities and a fluorescence 
microscope.  However, due to the lack of automation and significant reliance 
on manual scoring, results are highly operator dependent and the process of 
data acquisition is relatively laborious and time consuming. Data 
misinterpretation and scoring inconsistencies may be the result of operator 
fatigue and inexperience.  In addition, the sensitivity of this method is limited 
by the low number of cells able to be evaluated (approximately 200 nuclei per 
slide), representing only a small sample of the potentially complex mixture of 
Page 13 of 21
14 
 
cytogenetically abnormal cells often found in CLL samples.  Therefore, 
conventional FISH is limited in its capacity to detect small sub-clones, which 
may become clinically relevant during the course of the disease. 
In an attempt to overcome these limitations, the microscope-based 
laser scanning cytometer (LSC) emerged in the mid-1990s (18-20), and has 
since been updated with the new iGeneration of LSC Research Imaging 
Cytometer (e.g. iCys by Compucyte) and complemented by analysis software 
(21-23). These advances have allowed large-scale automated quantification 
of conventional FISH data. The two main advantages of the LSC method, 
compared to the conventional FISH method, is that LSC is able to analyze a 
significantly larger number of cells, and the process of automated spot 
counting solves the problem of scorer fatigue and human error. 
The LSC method is not however without its limitations.  Firstly, the LSC 
machine itself represents expensive and highly specialized equipment; 
thereby access will be the limiting factor for most researchers or diagnostic 
centers in applying this method.  In terms of the actual method of signal 
detection, LSC detects cells by the primary contour (visualized as DAPI-
stained nuclei) and enumerates any hybridized probes by the secondary 
contour. However, both the hybridized probes and the nuclei can vary greatly 
in relative fluorescence intensities and size, requiring a large training range of 
acceptable contours to be established to ensure correct detection of all cells 
and hybridized probes.  The fluorescence signals can also occur at variable 
depths along the optical axis, which can also lead to incorrect spot counting 
per cell. Therefore, the accuracy of the spot counting analysis needs to be 
checked by manually scoring a random sample of the cells, in order to ensure 
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that these factors are not resulting in a flawed automated analysis. In addition, 
there are several parameters, which need to be established prior to scanning 
the slides, for example, the focal length of the camera needs to be adjusted 
according to the thickness of the covering glass and the sample itself. 
Considering these factors, the application of LSC in FISH analysis is 
considered a semi-automated procedure (20, 24).  
By contrast, FISH-IS is able to provide accurate data generated from 
thousands of cells by analyzing the fluorescence intensity of the samples. 
However, this method relies heavily on maintaining the original morphology of 
the cells, as broken or disrupted cells are automatically excluded from the 
analysis.  For our CLL samples, analysis was compromised when using 
previously frozen and/or long term fixed samples.  This may be a feature of 
CLL cells specifically, or a more general issue with this method.  Regardless, 
the applicability of the FISH-IS method may be limited by sample availability.  
With respect to the financial cost of these three methods, the obvious 
difference is the specialized equipment required for the two high-throughput 
methods. That factor aside, all methods cost approximately the same for 
consumables, however the LSC and FISH-IS methods are less labor-intensive 
than conventional FISH. Experienced scorers spend approximately 2 hours to 
score 200 nuclei on conventional FISH, whilst the LSC and FISH-IS need 30 
minutes to 1 hour for analysis up to 3000 cells in LSC and up to 10,000 cells 
in FISH-IS. Therefore, the labor time of the later methods reduces significantly 
and the results do not depend heavily on experienced scores.  
While the role of trisomy 12 in CLL itself is not yet fully understood, Dohner et. 
al. (2) reported that trisomy 12 is the third most frequent chromosomal 
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aberrations in CLL, found in 16% of all cases, and in isolation, confers an 
intermediate outcome. Other studies have since found that trisomy 12 may 
actually be associated with either a good or a poor prognosis (25, 26). These 
conflicting findings may be due to differences in the proportion of CLL cells 
carrying trisomy 12 and additional mutations present in the sub-clones.  
Gonzalez-Gascon et al. found that trisomy 12 had to be present in >60% of 
CLL cells to confer a poor outcome (27).  Moreover, trisomy 12 often emerges 
in early stage CLL therefore may act as a driver mutation for secondary 
genetic alterations (e.g. NOTCH1 and TP53 mutations) (8, 10, 28, 29).  
Therefore, the detection of sub-clones carrying trisomy 12 appears important 
in the understanding of the biology of the disease eventually resulting in 
diagnostic and prognostic information which ultimately effects treatment 
decisions.   
It is noteworthy that the signal intensity generated using a centromere probe 
is vastly different from single allele probes making analysis of important 
chromosomal aberrations such as del17p and del11q difficult to demonstrate 
by FISH-IS. The next focus for this analysis is to further modify the high-
throughput methodologies to be applicable for smaller intra-chromosomal 
aberrations commonly found in CLL, such as del11q, del13p, and del17p. This 
is the subject of our ongoing research.   
FISH-IS is a dynamic methodology which is able to accurately analyze whole 
chromosome genetic aberrations, and hence provides an important research 
tool. While the diagnostic clinical laboratory would benefit from automation of 
cytogenetic analysis the best means of accomplishing this remains to be 
determined. Additionally, this methodology may well have other applications in 
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medicine such as the sensitive detection of fetal cell aneuploidy in maternal 
blood samples. Irrefutably however, the ability to detect low frequency clones 
in CLL is a vital part of prognostic determination and treatment decision 
making therefore we must continue to investigate the best means of providing 
that information to the treating clinicians.  
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Figure 1. FISH-IS is able to accurately differentiate monosomy from disomy 
by the fluorescence intensity of an X centromere probe in CLL samples. (A) 
Fluorescence intensity and normalized frequency indicate two populations of 
cells. (B) Single CLL cells discriminate into two populations based on raw max 
pixel and fluorescence intensity of the Spectrum Green X-chromosome 
centromere probe. Each spot represents one cell. (C) Examples of CLL cells 
with monosomy X (top panel) and disomy X (bottom panel).  Nuclear staining 
(DAPI) is shown in purple, centromere X probes are shown in green 
(Spectrum Green). (D) FISH-IS algorithm spot count (Spot Wizard) with 
centromere X probes from IDEAS software. The percentages of 1-spot gate 
were 21.8%, 2-spots 70.9% and 3-spots 7.3%. Representative results shown 
are from mixed 10% male CLL and 90% female CLL PBMCs.  Data is 
representative of three separate experiments per ratio, for all ratios analyzed 
in Supplementary Table 2. 
 
Figure 2. Correlation of observed versus expected monosomy X percentages 
in mixing experiments (male: female). Samples analyzed by fluorescence 
intensity using FISH-IS. 
 
Figure 3.  Correlation of the observed proportions of spot-count (Spot Wizard) 
analysis and the expected percentage spots of centromere Y, 9, X and 12 
probes using FISH-IS. 
 
Figure 4.  FISH-IS is able to enumerate centromere X spots in CLL cells 
merely by manual curation of the Spot Wizard. (A) Histogram of fluorescence 
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intensity of hybridized probe gated for cells automatically identified as having 
1-spot by Spot Wizard. (B) Histogram of fluorescence intensity of hybridized 
probe gated for cells automatically identified as having 2-spots by Spot 
Wizard.  (C) Overlapping fluorescence intensity of (A) and (B), indicating that 
the majority of cells automatically identified as having 1-spot actually have 2-
spots based on fluorescence intensity.  (D) Examples of cell images in R1 
gate, two spots closed (left panel), two spots overlapping partially (center 
panel) or completely (right panel). (E) Examples of cells that were inaccurately 
recorded as having three hybridization signals by Spot Wizard software as the 
spot(s) located outside the nuclei. (F) Manual correction of gating based on 
Spot Wizard shows 10.0% of cells have one spot and 89.9% of cells have two 
spots.  Nuclear staining (DAPI) is shown in purple, centromere X probes are 
shown in green (Spectrum Green).  Data is representative of three different 
experiments. 
 
Figure 5. Correlation of three methods with centromere 12 probes results in 
detecting CLL samples with different percentages of trisomy 12. (A) 
Comparing iCys and FISH-IS with standard slide FISH. (B) Linear regression 
and R2 values > 0.99 of LSC and FISH-IS while comparing with conventional 
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